PMID- 36286773
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221027
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 93
IP  - 4
DP  - 2021 Apr 15
TI  - [Analysis of the effectiveness of multiple myeloma treatment based on the 
      clinical experience of European countries].
PG  - 404-414
LID - 10.26442/00403660.2021.04.200682 [doi]
AB  - AIM: The main aim of this study was to model the effectiveness of multiple 
      myeloma (MM) therapy using machine learning, which was based on the analysis of 
      various methods of MM treatment, a number of prognostic factors and their results 
      in the daily routine clinical practice of medical centers in European countries. 
      MATERIALS AND METHODS: The present study was retrospective, non-interventional, 
      multicenter. A structured database of MM patients provided by the Oncology 
      Information service (O.I.s.) was used for the study. Registration took place in 
      medical institutions in eight countries: Austria, Belgium, Switzerland, Germany, 
      Spain, France, Greece and Great Britain. RESULTS: In total, 57% of men and 43% of 
      women were analyzed in the base of 6074 patients with MM. The median age was 71 
      years. The median follow-up time along the lines was 387 days. High-risk 
      cytogenetics are represented in 15% of cases. The efficacy endpoint was the best 
      response to each line of therapy, as measured by time to death (TTD) as an 
      indirect indicator of overall survival and time to next treatment (TTNT) as an 
      indirect indicator of progression-free survival. The median TTD and TTNT were 730 
      and 399 days respectively. After a multi-step selection process, characteristics 
      with the greatest importance for the therapy prognosis were selected: age at the 
      beginning of therapy, line of therapy, time after MM verification, ECOG (Eastern 
      Cooperative Oncology Group), cytogenetic risk, transplant eligibible or not, TTNT 
      after the previous line of therapy, therapy regimen. DISCUSSION: To continue the 
      study it is necessary to analyze literature data and compare with real practice. 
      Also analysis and comparison with Russian data on the treatment of patients with 
      MM is required. CONCLUSION: The analysis of the presented data provides a basis 
      for modeling a tool for assessing the effectiveness of MM therapy (prognosis of 
      TTD and TTNT) for each patient, based on a number of prognostic factors and the 
      results of routine clinical practice in various medical centers in European 
      countries.
FAU - Ptushkin, V V
AU  - Ptushkin VV
AUID- ORCID: 0000-0002-9368-6050
AD  - Pirogov Russian National Research Medical University.
AD  - Rogachev National Medical Research Center of Pediatric Hematology, Oncology and 
      Immunology.
AD  - Botkin City Clinical Hospital.
FAU - Mueller, M
AU  - Mueller M
AUID- ORCID: 0000-0002-3528-5208
AD  - University of Mannheim.
AD  - Analytical company IQVIA.
LA  - rus
PT  - English Abstract
PT  - Journal Article
DEP - 20210415
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
SB  - IM
OTO - NOTNLM
OT  - ECOG score
OT  - cytogenetic risk
OT  - multiple myeloma
OT  - overall survival
OT  - progression-free survival
OT  - stem cell transplantation
OT  - time to death
OT  - time to next therapy
EDAT- 2021/04/15 00:00
MHDA- 2021/04/15 00:01
CRDT- 2022/10/26 09:54
PHST- 2021/06/02 00:00 [received]
PHST- 2021/06/02 00:00 [accepted]
PHST- 2022/10/26 09:54 [entrez]
PHST- 2021/04/15 00:00 [pubmed]
PHST- 2021/04/15 00:01 [medline]
AID - 10.26442/00403660.2021.04.200682 [doi]
PST - epublish
SO  - Ter Arkh. 2021 Apr 15;93(4):404-414. doi: 10.26442/00403660.2021.04.200682.